Opinion

Video

Bladder Cancer: Highlights from ESMO 2023 and Ongoing Developments

Author(s):

Axel Merseburger, MD, PhD,M. Carmen Mir, MD, PhD

The expert panel reviews highlights from ESMO 2023 and discusses ongoing developments in the treatment landscape for bladder cancer.

Related Videos
2 KOLs are featured in this series.
Tiago Biachi, MD, PhD
2 KOLs are featured in this series.
Adam E. Singer, MD, PhD, Health Sciences Clinical Instructor, medicine, division lead, kidney cancer, Division of Hematology/Oncology, UCLA Health
2 KOLs are featured in this series.
2 KOLs are featured in this series.
Related Content
David A. Braun, MD, PhD
November 9th 2024

Post Hoc Analysis Reveals Potential Serum Glycoproteomic Biomarkers for Nivolumab/Cabozantinib in Advanced RCC

Oncology Unplugged
November 6th 2024

Review Key Genitourinary Cancer Data From the 2024 ESMO Congress With Chandler Park, MD

BT7480 in Nectin-4+, CD137+ Tumors | Image Credit: © Katsyarina - stock.adobe.com
November 7th 2024

BT7480 Shows Preliminary Activity in Nectin-4+, CD137+ Tumors

Aaron T. Gerds, MD, MS, assistant professor, Department of Medicine, School of Medicine, member, Developmental Therapeutics Program, Case Comprehensive Cancer Center, physician,Department of Hematology and Medical Oncology, Cleveland Clinic; James K. McCloskey, MD, interim chief, Division of Leukemia, Hackensack John Theurer Cancer Center
October 14th 2024

Navigating Myelofibrosis: Updates for Community Hematologist Oncologists

ESMO 2024
November 1st 2024

The Top News From ESMO 2024: A Variety of Data Inform Solid Tumor Landscapes

FDA
October 31st 2024

FDA Grants Regenerative Medicine Advanced Therapy Designation to ALLO-316 in CD70+ Advanced RCC